Is GAN or PFE a better dividend investment in 2026?

GAN currently yields 101.52% with a 5% 5-year dividend growth rate. PFE yields 6.20% with 4.1% growth. The better choice depends on your goal: GAN offers higher current income.

What is the dividend yield difference between GAN and PFE?

GAN has a forward dividend yield of 101.52% ($2.00/share annually). PFE yields 6.20% ($1.72/share annually). The yield gap is 95.32 percentage points.

Home › Compare › GAN vs PFE

GAN vs PFE: Dividend Comparison 2026

GAN yields 101.52% · PFE yields 6.20%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 GAN wins by $4.09M in total portfolio value

INVESTMENT

TIME HORIZON10 years

GAN

● Live price

101.52%

Share price

$1.97

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.15M

Annual income

$1,411,051.39

Full GAN calculator →

PFE

Pfizer Inc.

● Live price

6.20%

Share price

$27.76

Annual div

$1.72

5Y div CAGR

13.2%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$51.1K

Annual income

$27,210.54

Full PFE calculator →

Portfolio growth — GAN vs PFE

📍 GAN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	GAN	PFE
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, GAN + PFE cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

GAN pays

PFE pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GAN

Annual income on $10K today (after 15% tax)

$8,629.44/yr

After 10yr DRIP, annual income (after tax)

$1,199,393.68/yr

PFE

Annual income on $10K today (after 15% tax)

$526.66/yr

After 10yr DRIP, annual income (after tax)

$23,128.96/yr

At 15% tax rate, GAN beats the other by $1,176,264.72/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GAN + PFE for your $10,000?

GAN: 50%PFE: 50%

100% PFE50/50100% GAN

Portfolio after 10yr

$2.10M

Annual income

$719,130.97/yr

Blended yield

34.27%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

GAN

Analyst Ratings

Buy

Hold

Consensus: Hold

Altman Z

-3.6

Piotroski

3/9

PFE

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

Price Target

$27.50

-0.9% upside vs current

Range: $24.00 — $35.00

Altman Z

2.0

Piotroski

5/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GAN buys

PFE buys

No recent congressional trades found for GAN or PFE in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricGANPFE

Forward yield	101.52% ✓	6.20%
Annual dividend / share	$2.00 ✓	$1.72
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	13.2% ✓
Portfolio after 10y	$4.15M	$51.1K ✓
Annual income after 10y	$1,411,051.39 ✓	$27,210.54
Total dividends collected	$3.71M	$60.1K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare
Analyst consensus	Hold	Hold

Year-by-year: GAN vs PFE ($10,000, DRIP)

Year	GAN Portfolio	GAN Income/yr	PFE Portfolio	PFE Income/yr	Gap
1← crossover	$20,852	$10,152.28	$9,161	$701.38	+$11.7K → GAN
2	$42,097	$19,784.89	$8,610	$859.79	+$33.5K → GAN
3	$82,373	$37,328.94	$8,366	$1,081.25	+$74.0K → GAN
4	$156,403	$68,264.51	$8,483	$1,405.66	+$147.9K → GAN
5	$288,488	$121,136.25	$9,084	$1,907.24	+$279.4K → GAN
6	$517,502	$208,819.97	$10,418	$2,732.78	+$507.1K → GAN
7	$903,811	$350,084.51	$13,007	$4,193.56	+$890.8K → GAN
8	$1,538,498	$571,419.57	$18,010	$7,005.87	+$1.52M → GAN
9	$2,555,248	$909,055.50	$28,216	$12,979.89	+$2.53M → GAN
10	$4,145,167	$1,411,051.39	$51,081	$27,210.54	+$4.09M → GAN

GAN vs PFE: Complete Analysis 2026

GAN — Stock

GAN Limited operates as a business-to-business (B2B) supplier of enterprise software-as-a-service solutions to online casino gaming and sports betting applications in the United States, Europe, Latin America, and internationally. The company operates in two segments, B2B and Business-to-Consumer (B2C). It offers and licenses GameSTACK, an internet gaming platform that provides turnkey technology solution for regulated real-money internet gambling, online sports betting, and virtual simulated gaming. The company also offers online sports betting, online casino game, and peer-to-peer poker services through its coolbet.com website, as well as a range of development, marketing, and customer support services designed to deploy and provide ongoing operational support for its software systems. It serves regional operators and individual tribal casino operators. The company was incorporated in 1999 and is headquartered in Irvine, California.

Full GAN Calculator →

PFE — Healthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →

📬

Get this GAN vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GAN vs SCHD GAN vs JEPI GAN vs O GAN vs KO GAN vs MAIN GAN vs JNJ GAN vs MRK GAN vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.